Lanean...
Sunitinib in the treatment of metastatic renal cell carcinoma
Sunitinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that targets various receptors, including vascular endothelial growth factor receptors (VEGFRs). Sunitinib received approval in 2006 and became a standard treatment option in the first-line treatment of metastatic renal cell cancer...
Gorde:
| Argitaratua izan da: | Ther Adv Urol |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
SAGE Publications
2016
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5117167/ https://ncbi.nlm.nih.gov/pubmed/27904651 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287216663979 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|